<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01211028</url>
  </required_header>
  <id_info>
    <org_study_id>0405402</org_study_id>
    <nct_id>NCT01211028</nct_id>
  </id_info>
  <brief_title>Adipose CELL Derived Regenerative Endothelial Angiogenic Medicine</brief_title>
  <acronym>ACELLDREAM</acronym>
  <official_title>Safety of Autologous Adipose Derived Stroma/Stem Cells to Treat Critical Leg Ischemia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>French Blood Establishment (Midi-Pyrénées)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinical Research Center, Toulouse</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre National de la Recherche Scientifique, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the safety and feasibility of regenerative
      therapy with expanded adipose derived stroma/stem cells sue, administered intramuscularly in
      patients with critical leg ischemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and Nature of Adverse Events : safety and tolerability</measure>
    <time_frame>15 days, 1, 2, 3, 4,5, 6 months for adverse events record</time_frame>
    <description>To evaluate safety and tolerability related to the intramuscular injection of autologous adipose derived stroma/ stem cells. [ Designated as safety issue: Yes ]</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Peripheral Vascular Diseases</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Autologous ASCs</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Expanded autologous ASCs (Adipose Stroma/Stem Cells) Intramuscular dose of 100 million expanded cells.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Expanded autologous ASCs</intervention_name>
    <description>Drug: Expanded autologous adipose-derived adult stroma/stem cells</description>
    <arm_group_label>Autologous ASCs</arm_group_label>
    <other_name>Expanded autologous Adipose-derived adult Stroma/Stem cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Severe peripheral vascular disease not amenable to bypass or angioplasty

          -  Age &gt;40 years old

          -  Normal renal function (creatinine &lt; 1.6)

          -  Non pregnant female

          -  Lifespan &gt; 6 months

        Exclusion Criteria:

          -  Age &lt;40 years old

          -  Refusal to give informed consent and/orCognitively disabled

          -  Congestive heart failure or stroke in the last 3 months

          -  History of cancer or myeloproliferative disorders

          -  Proliferative retinopathy

          -  Pregnancy

          -  Positive screening test for HIV, Hepatitis B or Hepatitis C

          -  Buerger patient

          -  Cachexia or predicted impossibility for a biopsy of at least 30 grams of fat tissue

          -  Pregnancy or lactation

          -  Having been non controlled severe pathology
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alessandra BURA-RIVIERE, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Toulouse, Rangueil</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Toulouse, Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Planat-Benard V, Silvestre JS, Cousin B, André M, Nibbelink M, Tamarat R, Clergue M, Manneville C, Saillan-Barreau C, Duriez M, Tedgui A, Levy B, Pénicaud L, Casteilla L. Plasticity of human adipose lineage cells toward endothelial cells: physiological and therapeutic perspectives. Circulation. 2004 Feb 10;109(5):656-63. Epub 2004 Jan 20.</citation>
    <PMID>14734516</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2010</study_first_submitted>
  <study_first_submitted_qc>September 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2010</study_first_posted>
  <last_update_submitted>May 10, 2017</last_update_submitted>
  <last_update_submitted_qc>May 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Critical leg ischemia</keyword>
  <keyword>Adipose derived Stroma/Stem Cells</keyword>
  <keyword>Autologous</keyword>
  <keyword>Angiogenesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

